There were no significant changes in FT4 (P=0.650) and Anti TPO (P=0.600) during 12 weeks of treatment with imatinib (Table 1). Open in a separate window Fig 1 TSH level at 0, 4 &12 weeks after imatinib therapy Open in a separate window Fig 2 Free T3 changes during 12 weeks of imatinib therapy Table 1 Baseline guidelines & changes during imatinib therapy thead th align=”remaining” rowspan=”1″ colspan=”1″ Parameter /th th align=”remaining” rowspan=”1″ colspan=”1″ 0 week /th th align=”remaining” rowspan=”1″ colspan=”1″ 4 weeks /th th align=”remaining” rowspan=”1″ colspan=”1″ P-value /th th align=”remaining” rowspan=”1″ colspan=”1″ 12 weeks /th th align=”remaining” rowspan=”1″ colspan=”1″ P-value /th /thead TSH mlu/L2.130.402.250.700.751.420.350.002Free T4 pg/ml1.010.061.040.070.191.030.050.65Free T3 pg/ml2.100.142.580.100.0122.670.100.007Anti TPO IU/ml11.37.215.311.30.8013.59.40.60Anti TG IU/ml22.810.922.512.20.22118.78.700.041 Open in a separate window DISCUSSION Although our effects showed statistically significant changes in TSH, Aftin-4 FT4 and anti-thyroglobulin during Aftin-4 study period, these changes were within normal laboratory values. statistically significant changes within reference ranges in serum concentrations of TSH (P=0.753 and 0.002), Free T3 (P=0.012 and 0.007) and Anti Thyroglobulin (P=0.221 and 0.041) one month before and 3 months after imatinib initiation, respectively. At the same time, there were no significant changes in serum Free T4 (P=0.196 and 0.650) and Anti TPO (P=0.807 and 0.600) concentrations. Summary This study showed some significant changes on thyroid function checks during imatinib therapy. However, all Aftin-4 of them were within the normal range without any clinical abnormalities in the course of treatment. We recommend other studies with larger sample size and longer duration of follow-up. strong class=”kwd-title” Keywords: Imatinib mesylate, Chronic myelogenous leukemia, Thyroid function checks Intro Imatinib mesylate, a tyrosine kinase inhibitor, is definitely a targeted therapy for chronic myelogenous leukemia (CML).1 Its function is related to inhibition of multiple tyrosine kinases such as Bcr- Abl, Platelet-derived growth element and C kit.2 Several side effects have been ascribed to imatinib; of them the most common is definitely peripheral edema.3-6 Tyrosine kinase inhibitors were shown to cause not only thyroid dysfunction in some instances7 but also may increase the levothyroxine dose in thyroidectomized individuals.8 However, these findings are mostly based on retrospective studies. Here, we assessed the effects of imatinib therapy on thyroid function checks inside a prospective manner. MATERIALS AND METHODS 16 (9 male and 7 female) newly diagnosed instances of Philadelphia chromosome positive CML in chronic phase were recruited with this prospective study. Patients receiving medications that may impact thyroid function including steroids, anticonvulsants e.g. phenytoin, iodine and iodine comprising drugs, rifampin and salicylates were excluded from the study. Those with any earlier thyroid disorders, hepatic dysfunction, renal dysfunction and some other major systemic ailments as well as acute and chronic infections were also excluded. Physical exam including careful thyroid exam was performed at each check out and 5cc of whole blood was from all qualified patients. Sera were stored at -80C until further analysis. Imatinib was prescribed at 300 mg/day time and individuals were evaluated at 4 and 12 weeks after treatment. TSH, Free T4, Free T3, Anti thyroid peroxidase (Anti TPO), and Anti thyroglobulin (Anti Tg) were measured by Chemiluminescence assay (CLIA) just before and after 4 and Rabbit Polyclonal to FBLN2 12 weeks after initiation of treatment. Statistical analyses were performed using SPSS software, version 18. Data offered as the meanSE and Wilcoxon authorized- rank test was used to compare related guidelines with baseline at numerous times. The study protocol was authorized by local medical ethics committee and knowledgeable consent was from all the participants. RESULTS In this prospective study, 16 eligible individuals with newly diagnosed CML and a mean age of 295 years were enrolled. 9 instances were male (57.1%) and 7 instances were woman (42.9%). Changes in thyroid function checks were compared with baseline at 4 and 12 weeks after imatinib therapy. There was statistically significant decrease in TSH level (P=0.002) at week 12 (Fig 1) and significant increase in Free T3 at week 4 (P=0.012) and 12 (P=0.007) (Fig 2) (Table 1). There were no significant changes in Feet4 (P=0.650) and Anti TPO (P=0.600) during 12 weeks of treatment with imatinib (Table 1). Open in a separate windows Fig 1 TSH level at 0, 4 &12 weeks after imatinib therapy Open in a separate windows Fig 2 Free T3 changes during 12 weeks of imatinib therapy Table 1 Baseline guidelines & changes Aftin-4 during imatinib therapy thead th align=”remaining” rowspan=”1″ colspan=”1″ Parameter /th th align=”remaining” rowspan=”1″ colspan=”1″ 0 week /th th align=”remaining” rowspan=”1″ colspan=”1″ 4 weeks /th th align=”remaining” rowspan=”1″ colspan=”1″ P-value /th th align=”remaining” rowspan=”1″ colspan=”1″ 12 weeks /th th align=”remaining” rowspan=”1″ colspan=”1″ P-value /th /thead TSH mlu/L2.130.402.250.700.751.420.350.002Free T4 pg/ml1.010.061.040.070.191.030.050.65Free T3 pg/ml2.100.142.580.100.0122.670.100.007Anti TPO IU/ml11.37.215.311.30.8013.59.40.60Anti TG IU/ml22.810.922.512.20.22118.78.700.041 Open in a separate window DISCUSSION Although our results showed statistically significant changes in TSH, Feet4 and anti-thyroglobulin during study period, these changes were within normal laboratory values. In addition, none of them of the individuals clinically developed indicators of thyroid dysfunction which further.